AbbVie vs Pfizer
ABBV and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABBV and PFE compare
AbbVie is the larger company, worth 3.1 times as much as Pfizer ($521B against $171B).
On earnings, Pfizer is cheaper: it trades at 39.4× trailing earnings, against 83.3× for AbbVie.
AbbVie grew revenue faster over the last twelve months (10.4% versus −0.21% for Pfizer).
AbbVie keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with 6.8% at Pfizer.
Both pay dividends: AbbVie yields 2.3% and Pfizer 5.7%.
Pfizer scores higher on the StockData Score (11 against 10 for AbbVie), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABBV | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $521B | $171B |
| Share price | $294.89 | $29.95 |
| Change, 1 year | 31.0% | 22.2% |
| Change, 5 years | 152% | −38.4% |
| Beta (5Y) | 0.29 | 0.44 |
| Employees | 57K | 75K |
| StockData Score | ||
| Total score | 10 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 2 |
| Health score | 2 | 2 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 83.3× | 39.4× (better) |
| P/S | 8.1× | 2.7× (better) |
| P/B | – | 2.0× |
| EV/EBITDA | 34.7× | 16.7× (better) |
| P/FCF | 28.6× | 15.5× (better) |
| FCF yield | 3.5% | 6.4% (better) |
| Fair value | $152.33 | $19.52 |
| Margin of safety | −93.6% | −53.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | −0.21% |
| Revenue growth, 5Y average | 6.0% | 8.5% (better) |
| Net income growth (TTM) | 67.7% (better) | −59.7% |
| EPS growth (TTM) | 68.6% (better) | −59.6% |
| EPS growth, 5Y average | −2.8% (better) | −3.6% |
| Profitability | ||
| Gross margin | 71.5% | 73.2% (better) |
| Operating margin | 26.2% | – |
| Net margin | 9.8% (better) | 6.8% |
| FCF margin | 28.3% (better) | 17.2% |
| Return on equity | – | 5.0% |
| Return on invested capital | 20.1% | – |
| Financial health | ||
| Debt / equity | – | 0.74 |
| Net debt / EBITDA | 3.81 (better) | 4.07 |
| Interest coverage | 5.8× | – |
| Current ratio | 0.81 | 1.27 (better) |
| Altman Z-score | 2.86 (better) | 2.03 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | 5.7% (better) |
| Payout ratio | 190% | – |
| Years of dividend growth | 11 | 15 (better) |
| Dividend growth, 5Y average | 6.6% (better) | 2.4% |
| Buyback yield | 0.29% | – |
| Shareholder yield | 2.6% | 5.7% (better) |
| Ownership | ||
| Held by institutions | 75.6% | 67.2% |
| Held by insiders | 0.09% | 0.03% |
| Insider net buying, 12 months | −$18.9M | $2.8M (better) |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 0.92% | 2.6% |
Go deeper
- ABBV stock overview
- ABBV income statement
- ABBV valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.